Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

European Patent Office: These 67 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "European Patent Office: These 67 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can AXUMIN (fluciclovine f-18) generic drug versions launch in the European Patent Office?

Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: European Patent Office Patent 1,978,015
Patent Title: COMPOSE PRECURSEUR DE COMPOSE ORGANIQUE MARQUE A L'HALOGENE RADIOACTIF (PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN LABELED ORGANIC COMPOUND)

AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug. There has been litigation on patents covering AXUMIN

The generic ingredient in AXUMIN is fluciclovine f-18. Additional details are available on the fluciclovine f-18 profile page.

When can ZTALMY (ganaxolone) generic drug versions launch in the European Patent Office?

Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: European Patent Office Patent 1,959,966
Patent Title: FORMES GALÉNIQUES DE GANAXOLONE ET PROCÉDÉS DE PREPARATION ET D'UTILISATION DE CELLES-CI (GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF)

ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.

When can ZUBSOLV (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch in the European Patent Office?

Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: European Patent Office Patent 2,101,740
Patent Title: NOUVELLE COMPOSITION PHARMACEUTIQUE NON SUSCEPTIBLE D'ABUS COMPRENANT DES OPIOÏDES (NEW NON-ABUSABLE PHARMACEUTICAL COMPOSITION COMPRISING OPIOIDS)

Drug Price Trends for ZUBSOLV
ZUBSOLV is a drug marketed by Edenbridge Pharms. There are ten patents protecting this drug and four Paragraph IV challenges. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering ZUBSOLV

See drug price trends for ZUBSOLV.

The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in the European Patent Office?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: European Patent Office Patent 2,086,940

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the European Patent Office?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: European Patent Office Patent 2,091,918

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the European Patent Office?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: European Patent Office Patent 2,190,826

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the European Patent Office?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: European Patent Office Patent 2,311,807

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the European Patent Office?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: European Patent Office Patent 2,537,830

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can LETAIRIS (ambrisentan) generic drug versions launch in the European Patent Office?

Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: European Patent Office Patent 2,101,777
Patent Title: COMPOSITION DE TRAITEMENT DE L'HYPERTENSION PULMONAIRE (COMPOSITION FOR TREATING A PULMONARY HYPERTENSION)

LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LETAIRIS

See drug price trends for LETAIRIS.

The generic ingredient in LETAIRIS is ambrisentan. Additional details are available on the ambrisentan profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in the European Patent Office?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: European Patent Office Patent 3,176,159

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in the European Patent Office?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: European Patent Office Patent 3,808,740

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in the European Patent Office?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: European Patent Office Patent 2,399,571
Patent Title: Compositions thérapeutiques comprenant de l'ingénol-2-angelate (Therapeutic compositions comprising ingenol-3-angelate)

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can VYKAT XR (diazoxide choline) generic drug versions launch in the European Patent Office?

Generic name: diazoxide choline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: European Patent Office Patent 1,968,601
Patent Title: SELS D'OUVREURS DES CANAUX POTASSIQUES ATP-DÉPENDANTS ET LEURS UTILISATIONS (SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF)

VYKAT XR is a drug marketed by Soleno. There are six patents protecting this drug. There has been litigation on patents covering VYKAT XR

The generic ingredient in VYKAT XR is diazoxide choline. Additional details are available on the diazoxide choline profile page.

When can VYKAT XR (diazoxide choline) generic drug versions launch in the European Patent Office?

Generic name: diazoxide choline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: European Patent Office Patent 2,404,604
Patent Title: Sels d'ouverture de canal ATP du potassium et leurs utilisations (Salts of potassium ATP channel openers and uses thereof)

VYKAT XR is a drug marketed by Soleno. There are six patents protecting this drug. There has been litigation on patents covering VYKAT XR

The generic ingredient in VYKAT XR is diazoxide choline. Additional details are available on the diazoxide choline profile page.

When can SEYSARA (sarecycline hydrochloride) generic drug versions launch in the European Patent Office?

Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2026
Generic Entry Controlled by: European Patent Office Patent 3,488,853
Patent Title: COMPOSÉS DE TÉTRACYCLINE SUBSTITUÉS POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES DE LA PEAU (SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS)

SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.

See drug price trends for SEYSARA.

The generic ingredient in SEYSARA is sarecycline hydrochloride. Additional details are available on the sarecycline hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the European Patent Office?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: European Patent Office Patent 2,495,016

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the European Patent Office?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: European Patent Office Patent 3,747,441

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in the European Patent Office?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: European Patent Office Patent 2,118,208
Patent Title: MÉTHODE DE PRÉPARATION DE PARTICULES COMPRENANT UN ENROBAGE D'OXYDE MÉTALLIQUE (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING)

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in the European Patent Office?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: European Patent Office Patent 2,545,776
Patent Title: Procédé de préparation de particules comprenant un revêtement d'oxyde métallique et particules à revêtement d'oxyde métallique (Method for preparing particles comprising metal oxide coating and particles with metal oxide coating)

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can NESINA (alogliptin benzoate) generic drug versions launch in the European Patent Office?

Generic name: alogliptin benzoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: European Patent Office Patent 2,124,901
Patent Title: PRÉPARATION DE COMPRIMÉ NE PROVOQUANT PAS DE PROBLÈME DE PASTILLAGE (TABLET PREPARATION WITHOUT CAUSING A TABLETING TROUBLE)

Drug Price Trends for NESINA
NESINA is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering NESINA

See drug price trends for NESINA.

The generic ingredient in NESINA is alogliptin benzoate. Additional details are available on the alogliptin benzoate profile page.

When can MACRILEN (macimorelin acetate) generic drug versions launch in the European Patent Office?

Generic name: macimorelin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 19, 2027
Generic Entry Controlled by: European Patent Office Patent 1,984,744

MACRILEN is a drug marketed by Aeterna Zentaris. There is one patent protecting this drug.

See drug price trends for MACRILEN.

The generic ingredient in MACRILEN is macimorelin acetate. Additional details are available on the macimorelin acetate profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in the European Patent Office?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: European Patent Office Patent 2,079,445

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in the European Patent Office?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: European Patent Office Patent 2,079,445

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can PRESTALIA (amlodipine besylate; perindopril arginine) generic drug versions launch in the European Patent Office?

Generic name: amlodipine besylate; perindopril arginine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 26, 2027
Generic Entry Controlled by: European Patent Office Patent 1,989,182

PRESTALIA is a drug marketed by Adhera. There is one patent protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering PRESTALIA

The generic ingredient in PRESTALIA is amlodipine besylate; perindopril arginine. Additional details are available on the amlodipine besylate; perindopril arginine profile page.

When can DYANAVEL XR (amphetamine) generic drug versions launch in the European Patent Office?

Generic name: amphetamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: European Patent Office Patent 2,428,205
Patent Title: Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions (Modified release formulations containing drug-ion exchange resin complexes)

Drug Price Trends for DYANAVEL XR
DYANAVEL XR is a drug marketed by Tris Pharma Inc. There are twelve patents protecting this drug. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering DYANAVEL XR

See drug price trends for DYANAVEL XR.

The generic ingredient in DYANAVEL XR is amphetamine. Additional details are available on the amphetamine profile page.

When can TUZISTRA XR (chlorpheniramine polistirex; codeine polistirex) generic drug versions launch in the European Patent Office?

Generic name: chlorpheniramine polistirex; codeine polistirex
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: European Patent Office Patent 2,428,205
Patent Title: Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions (Modified release formulations containing drug-ion exchange resin complexes)

TUZISTRA XR is a drug marketed by Tris Pharma Inc. There are two patents protecting this drug. There has been litigation on patents covering TUZISTRA XR

See drug price trends for TUZISTRA XR.

The generic ingredient in TUZISTRA XR is chlorpheniramine polistirex; codeine polistirex. Additional details are available on the chlorpheniramine polistirex; codeine polistirex profile page.

When can SPRAVATO (esketamine hydrochloride) generic drug versions launch in the European Patent Office?

Generic name: esketamine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: European Patent Office Patent 2,012,762
Patent Title: ADMINISTRATION INTRA-NASALE DE KETAMINE POUR TRAITER LA DEPRESSION (INTRANASAL ADMINISTRATION OF KETAMINE TO TREAT DEPRESSION)

Drug Price Trends for SPRAVATO
SPRAVATO is a drug marketed by Janssen Pharms. There are seven patents protecting this drug. There has been litigation on patents covering SPRAVATO

See drug price trends for SPRAVATO.

The generic ingredient in SPRAVATO is esketamine hydrochloride. Additional details are available on the esketamine hydrochloride profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in the European Patent Office?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: European Patent Office Patent 1,972,618

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in the European Patent Office?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: European Patent Office Patent 2,137,143

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch in the European Patent Office?

Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2027
Generic Entry Controlled by: European Patent Office Patent 2,136,793
Patent Title: FORMULATIONS POUR COMPRIMÉS CONTENANT DES SELS DE 8-[{1-(3,5-BIS- (TRIFLUOROMÉTHYL)PHÉNYL)-ÉTHOXY}-MÉTHYL]-8-PHÉNYL-1,7-DIAZA-SPIRO[4,5]- DÉCAN-2-ONE ET COMPRIMÉS (TABLET FORMULATIONS CONTAINING 8-[{1-(3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXY}-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE SALTS AND TABLETS MADE THEREFROM)

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

The generic ingredient in VARUBI is rolapitant hydrochloride. Additional details are available on the rolapitant hydrochloride profile page.

When can AMYVID (florbetapir f-18) generic drug versions launch in the European Patent Office?

Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 26, 2027
Generic Entry Controlled by: European Patent Office Patent 2,363,391

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. Additional details are available on the florbetapir f-18 profile page.

When can AMYVID (florbetapir f-18) generic drug versions launch in the European Patent Office?

Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 26, 2027
Generic Entry Controlled by: European Patent Office Patent 2,363,392

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. Additional details are available on the florbetapir f-18 profile page.

When can BYSANTI (milsaperidone) generic drug versions launch in the European Patent Office?

Generic name: milsaperidone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 29, 2027
Generic Entry Controlled by: European Patent Office Patent 2,134,873
Patent Title: PROCÉDÉ PERMETTANT DE PRÉDIRE UNE PRÉDISPOSITION À LA PROLONGATION DU QT (METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION)

BYSANTI is a drug marketed by Vanda Pharms Inc. There are ten patents protecting this drug. There has been litigation on patents covering BYSANTI

The generic ingredient in BYSANTI is milsaperidone. Additional details are available on the milsaperidone profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch in the European Patent Office?

Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 04, 2027
Generic Entry Controlled by: European Patent Office Patent 2,662,373

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

The generic ingredient in VARUBI is rolapitant hydrochloride. Additional details are available on the rolapitant hydrochloride profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch in the European Patent Office?

Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 04, 2027
Generic Entry Controlled by: European Patent Office Patent 2,662,374

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

The generic ingredient in VARUBI is rolapitant hydrochloride. Additional details are available on the rolapitant hydrochloride profile page.

When can INLYTA (axitinib) generic drug versions launch in the European Patent Office?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: European Patent Office Patent 2,134,702

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can INLYTA (axitinib) generic drug versions launch in the European Patent Office?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: European Patent Office Patent 3,252,047

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can INLYTA (axitinib) generic drug versions launch in the European Patent Office?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: European Patent Office Patent 4,074,702

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can INLYTA (axitinib) generic drug versions launch in the European Patent Office?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: European Patent Office Patent 4,249,063

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in the European Patent Office?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: European Patent Office Patent 2,007,756
Patent Title: MODULATEURS DES TRANSPORTEURS DE CASSETTES DE LIAISON DE L'ATP (MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in the European Patent Office?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: European Patent Office Patent 2,674,428
Patent Title: Modulateurs des transporteurs de cassettes de liaison de l'ATP (Modulators of ATP-binding cassette transporters)

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in the European Patent Office?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: European Patent Office Patent 3,091,011
Patent Title: MODULATEURS DE TRANSPORTEURS DE CASSETTE À LIAISON ATP (MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in the European Patent Office?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: European Patent Office Patent 3,327,016
Patent Title: PRÉPARATION DES MODULATEURS DE TRANSPORTEURS DE CASSETTE À LIAISON ATP (PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in the European Patent Office?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: European Patent Office Patent 3,882,245
Patent Title: MODULATEURS DE TRANSPORTEURS DE CASSETTE À LIAISON ATP (MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch in the European Patent Office?

Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: European Patent Office Patent 2,135,199

Drug Price Trends for QVAR REDIHALER
QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. Additional details are available on the beclomethasone dipropionate profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in the European Patent Office?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: European Patent Office Patent 2,152,237

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in the European Patent Office?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: European Patent Office Patent 3,090,730

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in the European Patent Office?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: European Patent Office Patent 4,218,732

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in the European Patent Office?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: European Patent Office Patent 4,218,733

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in the European Patent Office?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: European Patent Office Patent 4,400,104

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the European Patent Office?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: European Patent Office Patent 2,023,933

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the European Patent Office?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: European Patent Office Patent 2,024,366

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in the European Patent Office?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: European Patent Office Patent 2,155,696

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in the European Patent Office?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: European Patent Office Patent 2,164,473

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in the European Patent Office?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: European Patent Office Patent 3,666,263

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can CONTRAVE (bupropion hydrochloride; naltrexone hydrochloride) generic drug versions launch in the European Patent Office?

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 31, 2027
Generic Entry Controlled by: European Patent Office Patent 3,626,236
Patent Title: FORMULATION DE NALTREXONE À LIBÉRATION PROLONGÉE (SUSTAINED RELEASE FORMULATION OF NALTREXONE)

CONTRAVE is a drug marketed by Azurity. There are eighteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in the European Patent Office?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: European Patent Office Patent 2,164,467

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in the European Patent Office?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: European Patent Office Patent 2,500,014

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in the European Patent Office?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: European Patent Office Patent 3,431,077

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in the European Patent Office?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: European Patent Office Patent 2,164,467

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in the European Patent Office?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: European Patent Office Patent 2,500,014

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in the European Patent Office?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: European Patent Office Patent 3,431,077

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in the European Patent Office?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: European Patent Office Patent 2,173,752

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in the European Patent Office?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: European Patent Office Patent 3,070,090

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in the European Patent Office?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: European Patent Office Patent 3,495,369

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in the European Patent Office?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: European Patent Office Patent 4,011,883

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in the European Patent Office?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: European Patent Office Patent 2,069,383
Patent Title: COMPOSITION, PROCÉDÉ ET PRÉPARATION D'ACIDE BILIAIRE SYNTHÉTIQUE (SYNTHETIC BILE ACID COMPOSITION, METHOD, AND PREPARATION)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in the European Patent Office?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: European Patent Office Patent 3,002,290
Patent Title: SYNTHESE D'ACIDE DESOXYCHOLIQUE (DCA) (SYNTHESIS OF DEOXYCHOLIC ACID (DCA))

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can CARDAMYST (etripamil) generic drug versions launch in the European Patent Office?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: European Patent Office Patent 2,170,050
Patent Title: Agents bloquant les canaux calciques à base de phénylalkylamine à brève durée d'action et leurs utilisations (Short acting phenylalkylamine calcium channel blockers and uses thereof)

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can BYDUREON (exenatide synthetic) generic drug versions launch in the European Patent Office?

Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: European Patent Office Patent 2,457,918

Drug Price Trends for BYDUREON
BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. Additional details are available on the exenatide synthetic profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch in the European Patent Office?

Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: European Patent Office Patent 2,457,918

Drug Price Trends for FARXIGA
FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Fifteen tentatively approved generics are ready to enter the market. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. Additional details are available on the dapagliflozin profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in the European Patent Office?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: European Patent Office Patent 2,457,918

Drug Price Trends for QTERN
QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in the European Patent Office?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: European Patent Office Patent 2,081,921
Patent Title: SELS DE BENZODIAZÉPINE ET LEURS FORMES POLYMORPHES À ACTION BRÈVE (SHORT-ACTING BENZODIAZEPINE SALTS AND THEIR POLYMORPHIC FORMS)

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can TWIRLA (ethinyl estradiol; levonorgestrel) generic drug versions launch in the European Patent Office?

Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: European Patent Office Patent 2,167,001
Patent Title: DISPOSITIF D'ADMINISTRATION THERMIQUE AVEC SOUDURE ULTRASONORE (DERMAL DELIVERY DEVICE WITH ULTRASONIC WELD)

Drug Price Trends for TWIRLA
TWIRLA is a drug marketed by Agile. There are three patents protecting this drug. Two tentatively approved generics are ready to enter the market.

See drug price trends for TWIRLA.

The generic ingredient in TWIRLA is ethinyl estradiol; levonorgestrel. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in the European Patent Office?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: European Patent Office Patent 2,164,844
Patent Title: DÉRIVÉS DE PYRIMIDINYLPYRIDAZINONE (PYRIMIDINYL PYRIDAZINONE DERIVATES)

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can MULPLETA (lusutrombopag) generic drug versions launch in the European Patent Office?

Generic name: lusutrombopag
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 31, 2027
Generic Entry Controlled by: European Patent Office Patent 2,184,279

MULPLETA is a drug marketed by Vancocin Italia. There are three patents protecting this drug.

See drug price trends for MULPLETA.

The generic ingredient in MULPLETA is lusutrombopag. Additional details are available on the lusutrombopag profile page.

When can SALONPAS (menthol; methyl salicylate) generic drug versions launch in the European Patent Office?

Generic name: menthol; methyl salicylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 01, 2027
Generic Entry Controlled by: European Patent Office Patent 2,047,845
Patent Title: PRÉPARATION ADHÉSIVE (ADHESIVE PREPARATION)

SALONPAS is a drug marketed by Hisamitsu Pharm Co. There are two patents protecting this drug.

The generic ingredient in SALONPAS is menthol; methyl salicylate. Additional details are available on the menthol; methyl salicylate profile page.

When can WINLEVI (clascoterone) generic drug versions launch in the European Patent Office?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: European Patent Office Patent 2,173,891
Patent Title: Procédé enzymatique pour obtenir le 17-alpha-propionate de cortexolone en forme cristalline III (Enzymatic process for obtaining cortexolone-17-alpha-propionate in crystalline form III)

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in the European Patent Office?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: European Patent Office Patent 2,503,004
Patent Title: Cortexolone-17alpha-propionate sous forme cristalline I (Cortexolone-17alpha-propionate in crystalline form I)

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in the European Patent Office?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: European Patent Office Patent 3,521,298
Patent Title: FORME CRISTALLINE III DE CORTEXOLONE-17-ALPHA-PROPIONATE ET SON UTILISATION PHARMACEUTIQUE (CORTEXOLONE-17-ALPHA-PROPIONATE CRYSTALLINE FORM III AND ITS PHARMACEUTICAL USE)

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in the European Patent Office?

Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 09, 2027
Generic Entry Controlled by: European Patent Office Patent 2,049,522
Patent Title: INHIBITEURS DU VIRUS DE L'HÉPATITE C (HEPATITIS C VIRUS INHIBITORS)

Drug Price Trends for DAKLINZA
DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. Additional details are available on the daclatasvir dihydrochloride profile page.

When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in the European Patent Office?

Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 09, 2027
Generic Entry Controlled by: European Patent Office Patent 2,385,048
Patent Title: Inhibiteurs du virus de l'hépatite C (Hepatitis C virus inhibitors)

Drug Price Trends for DAKLINZA
DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. Additional details are available on the daclatasvir dihydrochloride profile page.

When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in the European Patent Office?

Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 09, 2027
Generic Entry Controlled by: European Patent Office Patent 3,321,263
Patent Title: COMPOSÉS POUR LA PRÉPARATION D'INHIBITEURS DU VIRUS DE L'HÉPATITE C (COMPOUNDS FOR PREPARING HEPATITIS C VIRUS INHIBITORS)

Drug Price Trends for DAKLINZA
DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. Additional details are available on the daclatasvir dihydrochloride profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in the European Patent Office?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: European Patent Office Patent 2,187,965

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in the European Patent Office?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: European Patent Office Patent 3,388,086

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in the European Patent Office?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: European Patent Office Patent 3,656,403

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in the European Patent Office?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: European Patent Office Patent 3,831,380

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in the European Patent Office?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: European Patent Office Patent 3,838,298

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can VIZAMYL (flutemetamol f-18) generic drug versions launch in the European Patent Office?

Generic name: flutemetamol f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 30, 2027
Generic Entry Controlled by: European Patent Office Patent 2,182,988
Patent Title: COMPOSITION RADIOPHARMACEUTIQUE (RADIOPHARMACEUTICAL COMPOSITION)

VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.

See drug price trends for VIZAMYL.

The generic ingredient in VIZAMYL is flutemetamol f-18. Additional details are available on the flutemetamol f-18 profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in the European Patent Office?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: European Patent Office Patent 2,097,111

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in the European Patent Office?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: European Patent Office Patent 3,335,736

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in the European Patent Office?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: European Patent Office Patent 3,699,162

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in the European Patent Office?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: European Patent Office Patent 2,097,111

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in the European Patent Office?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: European Patent Office Patent 3,335,736

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in the European Patent Office?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: European Patent Office Patent 3,699,162

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in the European Patent Office?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: European Patent Office Patent 2,222,285
Patent Title: COMPOSITIONS PHARMACEUTIQUES (PHARMACEUTICAL COMPOSITIONS)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in the European Patent Office?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: European Patent Office Patent 3,143,992
Patent Title: COMPOSITIONS PHARMACEUTIQUES COMPRENNANT OXY-HYDROXIDE DE FER (PHARMACEUTICAL COMPOSITIONS COMPRISING IRON OXY-HYDROXIDE)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in the European Patent Office?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: European Patent Office Patent 3,492,069
Patent Title: COMPOSITIONS PHARMACEUTIQUES (PHARMACEUTICAL COMPOSITIONS)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in the European Patent Office?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: European Patent Office Patent 3,895,698
Patent Title: COMPOSITIONS PHARMACEUTIQUES CONTENANT DE L'OXYHROXYDE DE FER (PHARMACEUTICAL COMPOSITIONS COMPRISING IRON OXY-HYDROXIDE)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in the European Patent Office?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: European Patent Office Patent 3,895,699
Patent Title: COMPOSITIONS PHARMACEUTIQUES CONTENANT DE L'OXYHROXYDE DE FER (PHARMACEUTICAL COMPOSITIONS COMPRISING IRON OXY-HYDROXIDE)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in the European Patent Office?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: European Patent Office Patent 3,895,700
Patent Title: COMPOSITIONS PHARMACEUTIQUES CONTENANT DE L'OXYHYDROXYDE DE FER (PHARMACEUTICAL COMPOSITIONS COMPRISING IRON OXY-HYDROXIDE)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the European Patent Office?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: European Patent Office Patent 3,012,249

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in the European Patent Office?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: European Patent Office Patent 2,217,610
Patent Title: ANALOGUES D'AMINOGLYCOSIDES ANTIBACTÉRIENS (ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS)

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in the European Patent Office?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: European Patent Office Patent 3,150,617
Patent Title: ANALOGUES D'AMINOGLYCOSIDES ANTIBACTÉRIENS (ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS)

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in the European Patent Office?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: European Patent Office Patent 2,217,577

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in the European Patent Office?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: European Patent Office Patent 2,328,879

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in the European Patent Office?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: European Patent Office Patent 2,217,577

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in the European Patent Office?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: European Patent Office Patent 2,328,879

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in the European Patent Office?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: European Patent Office Patent 2,229,186
Patent Title: CONJUGUÉS GLUCIDIQUES UTILISÉS EN TANT QU'AGENTS D'ADMINISTRATION POUR DES OLIGONUCLÉOTIDES (CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES)

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in the European Patent Office?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: European Patent Office Patent 2,231,194
Patent Title: CONJUGUÉS DU FOLATE (FOLATE-IRNA CONJUGATES)

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in the European Patent Office?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: European Patent Office Patent 2,231,195
Patent Title: LIPIDES DE CIBLAGE (TARGETING LIPIDS)

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in the European Patent Office?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: European Patent Office Patent 3,141,265
Patent Title: CONJUGUÉS GLUCIDIQUES UTILISÉS COMME AGENTS D'ADMINISTRATION POUR DES OLIGONUCLÉOTIDES (CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES)

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in the European Patent Office?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: European Patent Office Patent 3,156,077
Patent Title: LIPIDES DE CIBLAGE (TARGETING LIPIDS)

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in the European Patent Office?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: European Patent Office Patent 3,705,125
Patent Title: CONJUGUÉS GLUCIDIQUES UTILISÉS EN TANT QU'AGENTS D'ADMINISTRATION POUR DES OLIGONUCLÉOTIDES (CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES)

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in the European Patent Office?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: European Patent Office Patent 4,074,344
Patent Title: LIPIDES DE CIBLAGE (TARGETING LIPIDS)

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in the European Patent Office?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: European Patent Office Patent 4,223,299
Patent Title: CONJUGUÉS GLUCIDIQUES UTILISÉS COMME AGENTS D'ADMINISTRATION POUR DES OLIGONUCLÉOTIDES (CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES)

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in the European Patent Office?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: European Patent Office Patent 4,321,177
Patent Title: CONJUGUÉS GLUCIDIQUES UTILISÉS COMME AGENTS D'ADMINISTRATION POUR DES OLIGONUCLÉOTIDES (CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES)

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in the European Patent Office?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: European Patent Office Patent 2,096,919
Patent Title: PRODUITS DÉRIVÉS DE 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE SUBSTITUÉS, UTILES POUR LE TRAITEMENT DE TROUBLES HYPERLIFÉRATIFS ET DE MALADIES ASSOCIÉES À UNE ANGIOGÉNÈSE (SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS)

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in the European Patent Office?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: European Patent Office Patent 3,683,218

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can LETAIRIS (ambrisentan) generic drug versions launch in the European Patent Office?

Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 11, 2027
Generic Entry Controlled by: European Patent Office Patent 2,952,193
Patent Title: COMPOSITION DE TRAITEMENT DE L'HYPERTENSION PULMONAIRE (COMPOSITION FOR TREATING A PULMONARY HYPERTENSION)

LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LETAIRIS

See drug price trends for LETAIRIS.

The generic ingredient in LETAIRIS is ambrisentan. Additional details are available on the ambrisentan profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in the European Patent Office?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 11, 2027
Generic Entry Controlled by: European Patent Office Patent 2,091,940

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in the European Patent Office?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 11, 2027
Generic Entry Controlled by: European Patent Office Patent 2,589,600

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in the European Patent Office?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: European Patent Office Patent 2,234,617

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in the European Patent Office?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: European Patent Office Patent 3,909,585

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can SEYSARA (sarecycline hydrochloride) generic drug versions launch in the European Patent Office?

Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2027
Generic Entry Controlled by: European Patent Office Patent 2,120,963
Patent Title: UTILISATION DE COMPOSÉS À BASE DE TÉTRACYCLINE SUBSTITUÉE DANS LE TRAITEMENT D'AFFECTIONS CUTANÉES INFLAMMATOIRES (SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS)

SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.

See drug price trends for SEYSARA.

The generic ingredient in SEYSARA is sarecycline hydrochloride. Additional details are available on the sarecycline hydrochloride profile page.

When can ONPATTRO (patisiran sodium) generic drug versions launch in the European Patent Office?

Generic name: patisiran sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 27, 2027
Generic Entry Controlled by: European Patent Office Patent 2,279,254
Patent Title: NOUVELLES FORMULATIONS LIPIDIQUES POUR L'ADMINISTRATION D'ACIDES NUCLÉIQUES (NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY)

ONPATTRO is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering ONPATTRO

See drug price trends for ONPATTRO.

The generic ingredient in ONPATTRO is patisiran sodium. Additional details are available on the patisiran sodium profile page.

When can RYTARY (carbidopa; levodopa) generic drug versions launch in the European Patent Office?

Generic name: carbidopa; levodopa
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 28, 2027
Generic Entry Controlled by: European Patent Office Patent 2,234,963
Patent Title: FORMULATIONS À LIBÉRATION CONTRÔLÉE DE LÉVODOPA ET LEURS UTILISATIONS (CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF)

RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering RYTARY

See drug price trends for RYTARY.

The generic ingredient in RYTARY is carbidopa; levodopa. Additional details are available on the carbidopa; levodopa profile page.

When can SOLUPREP (chlorhexidine gluconate; isopropyl alcohol) generic drug versions launch in the European Patent Office?

Generic name: chlorhexidine gluconate; isopropyl alcohol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 31, 2027
Generic Entry Controlled by: European Patent Office Patent 2,240,031
Patent Title: COMPOSITIONS ANTIMICROBIENNES (ANTIMICROBIAL COMPOSITIONS)

SOLUPREP is a drug marketed by Solventum.

The generic ingredient in SOLUPREP is chlorhexidine gluconate; isopropyl alcohol. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

European Patent Office Branded and Generic Drug Markets: Patent, Regulatory and Commercial Assessment

Last updated: October 13, 2026

The European pharmaceutical market combines strong originator protection with fragmented national pricing, reimbursement and market-access rules. The European Patent Office (EPO) grants European patents but does not approve medicines or determine reimbursement. Branded companies rely on European patents, supplementary protection certificates (SPCs), regulatory exclusivity and formulation or method-of-use rights. Generic and biosimilar companies rely on abbreviated regulatory pathways, the Bolar exemption, patent challenges and national launch strategies.

The main commercial opportunity is earlier generic and biosimilar entry across multiple European markets. The main risks are fragmented enforcement, unitary patent litigation, SPC disputes, manufacturing barriers, supply obligations and national reimbursement delays.

What role does the European Patent Office play in branded and generic drug markets?

The EPO examines and grants European patents under the European Patent Convention. It does not issue marketing authorizations, approve generic medicines or set medicine prices.

A granted European patent can be validated separately in designated countries or converted into a Unitary Patent covering participating EU member states. The EPO therefore affects market exclusivity, litigation exposure and launch timing, while the European Medicines Agency (EMA), national competent authorities and national payers control regulatory and commercial access.

Institution Primary function Relevance to drug markets
EPO Patent examination and grant Creates patent rights covering compounds, formulations, uses and manufacturing
Unified Patent Court (UPC) Centralized patent litigation for participating states Handles infringement and revocation disputes involving European and Unitary Patents
EMA Centralized marketing authorization for eligible medicines Reviews many innovative medicines and biosimilars
National regulators National and decentralized approvals Approve medicines outside or alongside the centralized route
European Commission Grants centralized EU marketing authorizations Converts EMA scientific opinions into EU-wide approvals
National payers Pricing and reimbursement Determine practical commercial access
European Commission and EU legislators Pharmaceutical and competition policy Establish regulatory exclusivity, generic pathways and market rules

The distinction between patent protection and regulatory protection is material. A medicine may have no remaining patent but still retain regulatory protection. Conversely, a patent may remain in force after regulatory exclusivity has expired.

What patents protect branded medicines in Europe?

Originator patent estates usually contain several layers of protection:

  1. Composition-of-matter patents for the active pharmaceutical ingredient.
  2. Salt, polymorph, stereoisomer and crystalline-form patents.
  3. Formulation and delivery-system patents.
  4. Manufacturing-process patents.
  5. Medical-use patents.
  6. Dosing-regimen and patient-subgroup patents.
  7. Combination-product patents.
  8. Device patents for autoinjectors, inhalers or pen systems.

The strongest right is generally a valid composition-of-matter patent with broad claim scope. Later formulation and method-of-use patents can delay or complicate generic entry, but their enforceability depends on claim construction, validity and the generic’s proposed label or product design.

What is the standard European patent term?

The standard patent term is 20 years from the earliest effective filing date, subject to renewal fees and national or unitary validation requirements. Patent term is not calculated from grant.

An SPC can extend protection for an active ingredient or qualifying combination by up to five years. A further six-month pediatric extension may be available when the regulatory requirements are satisfied. The maximum effective extension is generally five years and six months.[1]

Protection Typical duration Key condition
European patent 20 years from filing Valid grant and maintenance
SPC Up to 5 years Qualifying delay between patent filing and first authorization
Pediatric extension 6 months Completion of an approved pediatric investigation plan
Regulatory data exclusivity 8 years Generic or biosimilar cannot rely on originator dossier
Market protection 2 years after data exclusivity Generic authorization may be granted, but commercial launch is restricted
Additional market protection 1 year in limited cases Qualifying new therapeutic indication with significant benefit

When does a branded drug lose exclusivity in Europe?

Loss of exclusivity is determined by the earliest commercially relevant event among patent expiry, SPC expiry, regulatory exclusivity expiry and successful patent invalidation.

A typical European timeline is:

Year Event
Year 0 Patent filing
Years 0-8 Patent prosecution and clinical development
Around Year 10-12 First marketing authorization may be granted
Year 20 Basic patent expires, subject to national or unitary status
Up to Year 25 SPC may extend protection
Up to Year 25.5 Pediatric extension may apply
Authorization plus 8 years Generic or biosimilar dossier reliance becomes available
Authorization plus 10 years Market protection generally ends
Authorization plus 11 years Possible additional one-year protection for a qualifying new indication

The effective launch date for a generic depends on all enforceable rights, not on the basic patent alone. A generic company may file before patent expiry under the Bolar exemption, but commercial launch can still create infringement risk.

How do European generic and biosimilar pathways work?

Generic medicines normally use the Article 10 abridged application pathway under Directive 2001/83/EC. The applicant relies on the reference product’s quality, safety and efficacy data and demonstrates pharmaceutical equivalence or bioequivalence where required.[2]

Biosimilars follow a more complex pathway. The applicant must demonstrate high similarity to the reference biological medicine through analytical, nonclinical and clinical evidence. EMA reviews biosimilar applications through the centralized procedure in most cases.[3]

Generic versus biosimilar market access

Issue Generic Biosimilar
Product type Chemical small molecule Biological medicine
Core evidence Pharmaceutical quality and bioequivalence Comparative analytical and clinical similarity
Development cost Usually lower Higher
Manufacturing complexity Moderate to high High
Interchangeability Often governed nationally National policies remain important
Patent risk Compound, formulation and use patents Product, process, formulation and use patents
Launch pattern Multiple companies may enter quickly Fewer qualified manufacturers
Price erosion Often rapid Usually more gradual

Biosimilar companies face manufacturing and analytical barriers that can remain relevant after patent expiry. Cell-line development, process validation, comparability studies and supply capacity can limit the number of credible entrants.

What regulatory exclusivity protects originator medicines?

European regulatory protection is separate from patent protection. The standard framework is commonly described as “8+2+1”:

  • Eight years of data exclusivity.
  • Two additional years of market protection.
  • One possible additional year for a qualifying new therapeutic indication.

The generic or biosimilar applicant may prepare and submit an application during the exclusivity period, but reliance on the originator’s dossier and commercial launch remain restricted by the applicable rules.

Regulatory exclusivity applies at the authorization level and may differ in practical effect depending on whether the product uses the centralized, decentralized, mutual-recognition or national procedure. Orphan medicines have separate market-exclusivity rules, normally 10 years, with possible extension for pediatric compliance.[4]

What is the European equivalent of Orange Book patent listing?

The European Union has no single Orange Book equivalent that performs the same role as the U.S. Food and Drug Administration’s patent-listing system.

Patent information is distributed across:

  • EPO patent registers and Espacenet.
  • National patent registers.
  • Unitary Patent registers.
  • SPC registers.
  • National regulatory databases.
  • EMA product information.
  • Court filings and UPC case records.
  • Commercial patent and litigation databases.

This creates a higher diligence burden. A European launch assessment must identify the relevant country, patent status, validation status, SPC position, claim scope, regulatory pathway and litigation history. Patent declarations are not uniformly centralized across EU markets.

What is the Bolar exemption in Europe?

The Bolar exemption allows certain acts needed to obtain regulatory approval before patent expiry. The policy supports generic and biosimilar preparation without requiring the applicant to wait until the patent term ends.

The exemption is implemented through national law and may differ in scope. It can cover activities such as:

  • Development and testing.
  • Regulatory studies.
  • Bioequivalence work.
  • Manufacturing of samples.
  • Regulatory submission preparation.

The exemption does not automatically authorize commercial stockpiling, commercial sale or launch. Companies must assess the specific national implementation and the conduct at issue.

Which companies challenge branded drug patents in Europe?

Major generic and biosimilar participants active in European patent challenges include:

  • Teva.
  • Sandoz.
  • Viatris.
  • Zentiva.
  • Stada.
  • Krka.
  • Accord Healthcare.
  • Hikma.
  • Fresenius Kabi.
  • Organon.
  • Samsung Bioepis.
  • Celltrion.
  • Biocon Biologics.
  • Amgen.

Challenge strategies include opposition at the EPO, national invalidity actions, UPC revocation actions, non-infringement proceedings and regulatory filings designed to support a launch shortly after expiry.

The relevant challenger is product-specific. A company may oppose a patent without intending to launch in every country, while another company may preserve a commercial launch strategy through a settlement or license.

What patent litigation affects European drug launches?

European drug litigation is moving toward greater centralization but remains jurisdictionally complex.

EPO opposition

An EPO opposition can challenge a granted European patent within the prescribed opposition period. A successful opposition may revoke the patent centrally or narrow its claims across participating jurisdictions. Opposition outcomes can materially affect a generic launch plan.

Unified Patent Court

The UPC began operating on June 1, 2023. It can hear infringement and revocation disputes involving Unitary Patents and eligible European patents that have not been opted out.[5]

The UPC creates both opportunity and risk:

  • A patentee can seek a central injunction.
  • A challenger can pursue central revocation.
  • A single decision may affect multiple countries.
  • A weak patent can face broader invalidation exposure.
  • A preliminary injunction may disrupt a planned launch.

National courts remain relevant for opted-out European patents, non-participating states and matters outside UPC jurisdiction. Companies must map the patent’s territorial status before selecting a litigation strategy.

Settlement agreements

Patent settlements may include:

  • Agreed generic entry dates.
  • Licenses to launch before patent expiry.
  • Geographic carve-outs.
  • Authorized-generic arrangements.
  • Supply agreements.
  • Patent non-challenge provisions.
  • Royalty-bearing licenses.

Settlement terms must be reviewed for competition-law risk. The European Commission has scrutinized agreements that may delay generic entry or allocate markets.[6]

How strong is a European pharmaceutical patent estate?

Patent strength depends on legal, technical and commercial factors rather than the number of patent families.

Strength factor Strong position Weaker position
Core patent Broad, technically supported claims Narrow or vulnerable claims
Remaining term Multiple years after expected approval Expiry near regulatory launch
SPC Valid and centrally defensible Filing or eligibility defects
Formulation patent Essential to marketed product Easy design-around
Method-of-use patent Label-linked and clinically necessary Carve-out possible
Manufacturing patent Difficult process replication Alternative process available
Litigation history Claims upheld or narrowed favorably Repeated invalidity findings
Regulatory exclusivity Long remaining period Generic reliance already available
Supply chain Controlled manufacturing process Multiple qualified suppliers

An estate with a strong core patent and a valid SPC is generally more durable than an estate built mainly on late-filed formulation or dosing patents. Late patents can still matter when the formulation is commercially necessary or when a generic cannot practically avoid the patented use.

What formulation patents and method-of-use patents matter most?

Formulation patents often protect:

  • Extended-release systems.
  • Injectable depot formulations.
  • Lipid or nanoparticle carriers.
  • Stabilizers and excipient combinations.
  • Low-dose or high-concentration presentations.
  • Device-integrated delivery systems.
  • Temperature-stable formulations.
  • Pre-filled syringes and autoinjectors.

Method-of-use patents can cover:

  • A specific disease or indication.
  • A defined dosing interval.
  • Treatment of a biomarker-selected population.
  • Sequential or combination therapy.
  • Reduced toxicity or improved safety.
  • Switching from another therapy.
  • Maintenance treatment after induction.

A generic may seek a skinny label that excludes a patented indication. The commercial value of a skinny-label strategy depends on prescribing practice, substitution rules, pharmacy behavior and whether the patented use is the main demand driver.

What manufacturing and intellectual-property barriers affect generic entry?

Manufacturing barriers can delay entry even when patent protection has expired. Common barriers include:

  • Limited availability of active pharmaceutical ingredient suppliers.
  • Complex synthesis or purification.
  • Sterile manufacturing capacity.
  • Device assembly and human-factors validation.
  • Biological cell-line and process-development requirements.
  • Restricted access to reference standards.
  • Trade-secret protection around manufacturing processes.
  • Quality-system remediation.
  • Serialization and supply-chain requirements.

Process patents may create litigation exposure, but trade secrets and technical know-how can be equally important. A generic company may avoid an asserted process patent by using a different route, but it must still demonstrate regulatory equivalence and commercial reliability.

What are the geographic opportunities and challenges?

Europe is a collection of national pharmaceutical markets. A centralized authorization can simplify regulatory approval, but it does not create uniform pricing or reimbursement.

Geographic opportunities

  • Large patient populations in Germany, France, Italy, Spain and the United Kingdom.
  • Early generic penetration in markets with substitution and reference-pricing systems.
  • Premium pricing opportunities for differentiated formulations.
  • Biosimilar growth in hospital and specialty channels.
  • Cross-border manufacturing and supply-chain optimization.
  • Unitary Patent coverage for streamlined patent enforcement.

Geographic challenges

  • Different national reimbursement decisions.
  • Mandatory price reductions and tenders.
  • Local-language labeling and packaging.
  • National substitution rules.
  • Parallel trade.
  • Uneven generic uptake.
  • Separate litigation in non-UPC countries.
  • Procurement-driven margin pressure.

Germany often provides an important early commercial market because of its size and established generic utilization. France, Italy and Spain can offer substantial volume but may involve greater price and reimbursement pressure. Hospital products and biosimilars are particularly exposed to tender design and local procurement rules.

What is the commercial exposure from generic or biosimilar entry?

Revenue exposure depends on the product’s market structure, not only on patent expiry.

Product profile Typical entry exposure
Small-molecule tablet with many suppliers Rapid price erosion and high volume loss
Injectable with limited manufacturing capacity Slower erosion and fewer entrants
Complex formulation Moderate risk, depending on design-around options
Hospital biologic Tender-driven erosion and account-level switching
Specialty medicine with device Delayed or limited substitution
Orphan medicine Smaller volume but potentially high-value entry
Product with active settlement Controlled entry date and staged erosion

A single generic launch can reduce prices before multiple entrants appear. In hospital markets, tenders can cause abrupt share changes. In retail markets, substitution rules and pharmacy incentives often determine whether the originator retains demand after patent expiry.

How do licensing deals affect European generic and biosimilar competition?

Licensing can accelerate market entry and reduce litigation risk. Common structures include:

  • Voluntary licenses to selected generic manufacturers.
  • Regional licenses for non-EEA markets.
  • Biosimilar commercialization partnerships.
  • Authorized-generic supply arrangements.
  • Co-development agreements.
  • Manufacturing and technology-transfer licenses.
  • Device licenses for combination products.

Examples in the biosimilar sector include partnerships between biotechnology developers and multinational commercial organizations, such as Biocon Biologics and Viatris before Viatris transferred its biosimilars business to Biocon Biologics.[7] These transactions demonstrate that European competition may depend on manufacturing scale, regulatory dossiers and distribution rights as much as on patent validity.

What is the FDA and EMA regulatory status of European generic medicines?

The FDA and EMA are separate regulatory systems. An EMA or national EU authorization does not authorize sale in the United States, and FDA approval does not authorize sale in Europe.

For Europe, companies must determine whether the product requires:

  • Centralized authorization.
  • Decentralized procedure.
  • Mutual-recognition procedure.
  • National authorization.
  • Special pathway for biosimilars or advanced therapies.

The centralized procedure is mandatory for many innovative biological and high-technology products and is commonly used for biosimilars. Generic medicines may use centralized or national routes depending on product category and legal eligibility.[3]

What generic launch scenarios exist after patent expiry?

Three common launch scenarios are:

Clean launch

The relevant patents and SPCs have expired, no injunction is in force, and regulatory exclusivity has ended. Multiple companies may launch immediately.

Risk-adjusted launch

A generic launches after regulatory approval but before final resolution of a patent dispute. The company may use a non-infringement position, a carve-out label, an at-risk launch strategy or a settlement-based license.

Staged launch

The originator and challenger agree on an entry date, often with different dates by country. A license, authorized-generic arrangement or supply agreement may control the commercial rollout.

The most attractive targets combine high sales, expired regulatory exclusivity, weak secondary patents, available manufacturing capacity and predictable reimbursement.

Key Takeaways

  • The EPO grants patents; it does not approve drugs or set prices.
  • European drug exclusivity combines patents, SPCs, regulatory data protection and market protection.
  • The standard patent term is 20 years from filing, with a possible SPC of up to five years and a six-month pediatric extension.
  • Europe has no single Orange Book equivalent, increasing patent-status diligence requirements.
  • Generic companies can prepare regulatory submissions under the Bolar exemption, but commercial launch remains subject to enforceable rights.
  • The UPC creates opportunities for centralized revocation and infringement actions but increases the consequences of litigation.
  • Formulation, method-of-use, device and manufacturing rights can extend practical barriers after core compound-patent expiry.
  • Biosimilar entry is constrained by manufacturing, analytical and procurement requirements.
  • National reimbursement, substitution and tender systems determine commercial outcomes after approval.
  • Licensing and settlement agreements can materially change launch timing and competitive intensity.

FAQs on European branded and generic drug markets

How long after EMA approval can a generic launch in Europe?

A generic may generally rely on the reference product’s data after eight years, but market protection normally prevents commercial launch until 10 years after the reference authorization, subject to applicable extensions and product-specific rules.

Does a European patent automatically cover every EU country?

No. A conventional European patent requires validation in designated countries. A Unitary Patent covers participating EU member states, while some EU states and non-EU EPC states remain outside that unitary system.

Can a generic company launch before a European patent expires?

It may conduct qualifying regulatory-development activities under the Bolar exemption. Commercial launch before expiry can infringe an enforceable patent unless the product avoids the claims, uses a valid carve-out, relies on a license or prevails in litigation.

Are biosimilars automatically interchangeable across Europe?

No. EMA authorization establishes biosimilarity, but substitution and interchangeability policies are determined by national authorities and healthcare systems.

Can a company challenge a European patent without launching a generic?

Yes. A company may oppose or revoke a patent to remove a legal barrier, improve licensing leverage, protect future pipeline products or assist another commercial participant.

References

  1. European Patent Office. (2024). European patent guide: How to get a European patent. EPO.

  2. European Parliament and Council. (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use. EUR-Lex.

  3. European Medicines Agency. (2024). Generic and hybrid medicines. EMA.

  4. European Parliament and Council. (2006). Regulation (EC) No 1901/2006 on medicinal products for paediatric use. EUR-Lex.

  5. Unified Patent Court. (2023). Agreement on a Unified Patent Court and Rules of Procedure. UPC.

  6. European Commission. (2009). Pharmaceutical sector inquiry: Final report. European Commission.

  7. Biocon Biologics. (2022). Biocon Biologics completes acquisition of Viatris’ biosimilars business. Biocon Biologics.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.